Paralympic record progression track cycling – Women's 1 km time trial

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

Retrieved on: 
Wednesday, June 29, 2022
Weight gain, Oncology, CORT, Clinical Oncology, Patient, Probability, GLOBE, COVID-19, Union, Progression-free survival, Ovarian cancer, Disease, Goal, Intellectual property, Pancreatic cancer, Immune system, Publication, Woman, Liver disease, Cancer, Food, Doctor of Pharmacy, GR, Survival, SEC, NASDAQ, Paralympic record progression track cycling – Women's 1 km time trial, Recurrence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intention, Pharmaceutical industry, Medical imaging, Hospital, Corcept Therapeutics

The 20,000 women in the United States and an equal number in Europe with platinum-resistant ovarian cancer have few good treatment options.

Key Points: 
  • The 20,000 women in the United States and an equal number in Europe with platinum-resistant ovarian cancer have few good treatment options.
  • ROSELLA has a planned enrollment of 360 women with recurrent, platinum-resistant ovarian cancer, randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel monotherapy.
  • Additional information about ROSELLA and Corcepts Phase 2 trial results can be found at the publications and press releases tabs of www.corcept.com.
  • Corcept is studying relacorilant in a variety of serious disorders, including ovarian and adrenal cancer and Cushings syndrome.

Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

Retrieved on: 
Monday, June 6, 2022
Woman, Goal, Liver disease, Intellectual property, Weight gain, University of Milano-Bicocca, Survival, Food, Disease, Cancer, Probability, Pancreatic cancer, Ovarian cancer, University, European Institute of Oncology, Paralympic record progression track cycling – Women's 1 km time trial, European Institute, Patient, GR, COVID-19, Immune system, Union, SEC, Intention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Arm, Recurrence, Platinum, Pharmaceutical industry, Corcept Therapeutics

Results from the company's Phase 2 study in patients with recurrent, platinum-resistant ovarian cancer will be featured in an oral presentation at the ASCO Annual Meeting today.

Key Points: 
  • Results from the company's Phase 2 study in patients with recurrent, platinum-resistant ovarian cancer will be featured in an oral presentation at the ASCO Annual Meeting today.
  • Presentation Title: Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
  • Corcepts first controlled study in oncology relacorilant plus nab-paclitaxel for the treatment of patients with ovarian cancer has demonstrated statistically significant and clinically meaningful results.
  • Corcept is studying relacorilant in a variety of serious disorders, including ovarian and adrenal cancer and Cushings syndrome.

Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer

Retrieved on: 
Wednesday, March 30, 2022
Risk, Recurrence, University, Safety, Population, NASDAQ, Sale, See, Death, HIV disease progression rates, Board, Overalls, Corcept Therapeutics, Doctor of Pharmacy, Survival, Ovarian cancer, Woman, Neoplasm, Patient, Associate, CORT, OS, Â, PFS, MD, Dor, GLOBE, Paralympic record progression track cycling – Women's 1 km time trial, Gynecologic Oncology Group, GOG, Arm, Lists of diseases, FDA, Disease, Pharmaceutical industry

As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.

Key Points: 
  • As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.
  • In this large, randomized study, women with recurrent, platinum-resistant ovarian cancer who were administered relacorilant at the time they received nab-paclitaxel exhibited meaningful improvements in progression free survival, duration of response and overall survival without increased side effects compared to women who received nab-paclitaxel alone.
  • No approved therapy has been shown to significantly extend survival compared to standard chemotherapy in women with platinum-resistant ovarian cancer.
  • Fourteen additional women in the intermittent arm and nine additional women in the comparator arm are expected to contribute to the final overall survival results.